Trial Search Results
A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
The purpose of the study is to determine the efficacy and safety of enzastaurin in participants with Cutaneous T-Cell Lymphoma (CTCL) who failed prior therapies.
Stanford is currently not accepting patients for this trial.
Eli Lilly and Company
- Drug: Enzastaurin
- Histologically confirmed mycosis fungoides or Sezary Syndrome.
- Stage IB to IVB disease at screening.
- Recurrent or refractory disease after at least 1 prior systemic therapy.
- Have adequate organ function defined as:
- Hepatic: total bilirubin ≤1.5 times the upper limit of normal (ULN); alanine
transaminase/aspartate transaminase (ALT/AST) ≤2.5 times the ULN.
- Renal: serum creatinine ≤1.5 times the ULN.
- Adequate bone marrow reserve: platelets ≥75 * 10^9/Liters (L); absolute
neutrophil count (ANC) ≥1.0 * 10^9/L.
- At least 30 days must have passed since other treatment for CTCL.
- Receiving concurrent treatment for CTCL.
- Unable to swallow tablets.
- Receiving high potency oral or topical steroids. Low potency oral steroid may be
permitted in participants who have been on a stable dose for at least 4 weeks prior to
screening. Oral or topical antihistamine is allowed.
- Unable to discontinue use of carbamazepine, phenobarbital, or phenytoin.
- Have a serious concomitant systemic disorder or Human Immunodeficiency Virus (HIV).
- Have a serious cardiac condition such as myocardial infarction within past 6 months,
angina, or heart disease as defined by the New York Heart Association (NYHA) Class III
- Have electrocardiogram (ECG) abnormalities.
- Are pregnant or breastfeeding.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study